PRECEDE

PRECEDE – Pancreatic Cancer Early Detection

Pancreatic ductal adenocarcinoma (PDAC) is a disease with a poor prognosis, characterised by late diagnosis, early metastasis and, in most cases, therapeutic resistance. Several factors underlie the disease, such as PDAC predisposing pathogenic gene variants, long-standing diabetes, obesity and smoking. Research to date has shown that at least 10% of PDAC cases are familial, and that those with a confirmed family history of pancreatic cancer or germ cell mutations associated with PDAC risk are at increased risk of developing PDAC.

Screening of these high-risk individuals is the aim of the PRECEDE international consortium, which is investigating the causes and risk factors for PDAC. The aim is to improve the early detection and treatment of pancreatic cancer and thus improve survival.

Study leader: Prof. Dr. Péter Hegyi

Local coordinator: Zoltán Hajnády

Oncology Coordinator: Dr. Tamás Hussein

Oncology doctors: Prof. Dr. Zsuzsanna Kahán

                                 Dr. Orsolya Dohán

                                 Dr. Ágota Petrányi